Trial reportThe Journal of biological chemistry2012
PRELP protein inhibits the formation of the complement membrane attack complex.
Trial report in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 50 citations in OpenAlex.
- Protective effects of PRELP protein in a mouse model of pulmonary fibrosis.Respiratory research · 2026Article
- PRELP-associated transcriptomic remodeling links alternative splicing and immune checkpoint blockade outcome in melanoma.Frontiers in immunology · 2026Article
- PRELP functions via multiple interactions with intrinsically weak affinity relying on ECM anchoring and remodeling.Scientific reports · 2025Article
- Aging disrupts blood-brain and blood-spinal cord barrier homeostasis, but does not increase paracellular permeability.GeroScience · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.Journal of translational medicine · 2023Article
- PRELP secreted from mural cells protects the function of blood brain barrier through regulation of endothelial cell-cell integrity.Frontiers in cell and developmental biology · 2023Article
- Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway.Immunological reviews · 2023Review
- Single-Cell RNA-Seq Analysis of Cells from Degenerating and Non-Degenerating Intervertebral Discs from the Same Individual Reveals New Biomarkers for Intervertebral Disc Degeneration.International journal of molecular sciences · 2022Article
- Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation.Frontiers in immunology · 2022Article
- MicroRNA Profiling of the Tears of Children With Vernal Keratoconjunctivitis.Frontiers in genetics · 2022Article
- Small Leucine-Rich Proteoglycans (SLRPs) in the Retina.International journal of molecular sciences · 2021Review
- Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension.ESC heart failure · 2021Article
- A Proteomic Atlas of Cardiac Amyloid Plaques.JACC. CardioOncology · 2020Article
- A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis.Scientific reports · 2020Article
- Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics.ESC heart failure · 2020Article
- The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis.Arthritis research & therapy · 2016Article
- The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.Journal of internal medicine · 2015Review
- Proteoglycan form and function: A comprehensive nomenclature of proteoglycans.Matrix biology : journal of the International Society for Matrix Biology · 2015Review
- AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice.Gene therapy · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRELP is a 58-kDa proteoglycan found in a variety of extracellular matrices, including cartilage and at several basement membranes. In rheumatoid arthritis (RA), the cartilage tissue is destroyed and fragmented molecules, including PRELP, are released into the synovial fluid where they may interact with components of the complement system. In a previous study, PRELP was found to interact with the complement inhibitor C4b-binding protein, which was suggested to locally down-regulate complement activation in joints during RA. Here we show that PRELP directly inhibits all pathways of complement by binding C9 and thereby prevents the formation of the membrane attack complex (MAC). PRELP does not interfere with the interaction between C9 and already formed C5b-8, but inhibits C9 polymerization thereby preventing formation of the lytic pore. The alternative pathway is moreover inhibited already at the level of C3-convertase formation due to an interaction between PRELP and C3. This suggests that PRELP may down-regulate complement attack at basement membranes and on damaged cartilage and therefore limit pathological complement activation in inflammatory disease such as RA. The net outcome of PRELP-mediated complement inhibition will highly depend on the local concentration of other complement modulating molecules as well as on the local concentration of available complement proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.